Tyrosine Kinase Inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema.
Shruti ChandraEmanuel Yuquan TanTheo EmpeslidisSobha SivaprasadPublished in: Eye (London, England) (2023)
The advent of intravitreal anti-VEGF injections has revolutionised the treatment of both neovascular age-related macular degeneration (nAMD or wet AMD) and diabetic macular oedema (DMO). Despite their efficacy, anti-VEGF injections precipitate significant treatment burden for patients, caregivers and healthcare systems due to the high frequency of injections required to sustain treatment benefit. Therefore, there remains an unmet need for lower-burden therapies. Tyrosine kinase inhibitors (TKI) are a novel class of drugs that may have considerable potential in addressing this issue. This review will summarise and discuss the results of various pilot studies and clinical trials exploring the role of TKIs in treatment of nAMD and DMO, highlighting promising candidates and possible challenges in developments.
Keyphrases
- age related macular degeneration
- high frequency
- clinical trial
- healthcare
- type diabetes
- vascular endothelial growth factor
- end stage renal disease
- chronic kidney disease
- diabetic retinopathy
- optical coherence tomography
- transcranial magnetic stimulation
- risk assessment
- endothelial cells
- social media
- replacement therapy
- cataract surgery
- chronic myeloid leukemia
- open label
- wound healing
- tyrosine kinase
- epidermal growth factor receptor
- health information